Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells

Oncology Letters

Volumn 2, Issue 1, 2011, Pages 91-94

  Keda, Ryujii ^a   Vermeulen, Lee C ^b   Lau, Elim ^c   Jiang, Zhisheng ^c   Kavanaugh, Shannon M ^c   Yamada, Katsushi ^a   Kolesar, Jill M ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Fibroblast growth factor 2; P21

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 78751549460     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.198     Document Type: Article

References (19)

1. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. JClin Oncol 27: 6251-6266, 2009.
2. Hirsch FR, Varella-Garcia M and Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28: 32-37, 2009.
3. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl JMed 358: 1160-1174, 2008.
4. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
5. Mendelsohn Jand Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. JClin Oncol 21: 2787-2799, 2003.
6. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, LauDH, Crowley JJand Gandara DR: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. JClin Oncol 26: 2450-2456, 2008.
7. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. JClin Oncol 25: 1545-1552, 2007.
8. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, GoddemeierT, Emig M, Gatzemeier U; FLEX Study Team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531, 2009.
9. Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 29: 37-48, 2010.
10. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006.
11. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, MillerVA and Pao W: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501, 2006.
12. Kancha RK, von Bubnoff N, Peschel C and Duyster J: Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 15: 460-467, 2009.
13. Pawson T: Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116: 191-203, 2004.
14. Song S, Wientjes MG, Gan Y and Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97: 8658-8663, 2000.
15. Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, ZhangF, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P and Rafii S: Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 20: 979-986, 2006.
16. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19, 2008.
17. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
18. Sutter AP, Höpfner M, Huether A, Maaser K and Scherübl H: Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int JCancer 118: 1814-1822, 2006.
19. Ferrandiz N, Martin-Perez J, Blanco R, Donertas D, WeberA, Eilers M, Dotto P, Delgado MD and Leon J: HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair 8: 390-399, 2009.